<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 29 Apr 2021 17:26:38 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>改良新药「布地奈德缓释胶囊」获FDA优先审评，治疗IgA肾病！中国已纳入突破性疗法</title><link>https://mp.weixin.qq.com/s/h3-eMjzCPK8MbTZvJYkKeg</link><description></description><content:encoded><![CDATA[改良新药「布地奈德缓释胶囊」获FDA优先审评，治疗IgA肾病！中国已纳入突破性疗法]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>20年来首个全新机制抗流感新药！罗氏「玛巴洛沙韦片」在华获批上市</title><link>https://mp.weixin.qq.com/s/a58JjTlbEYpk-N2WaHKk-Q</link><description></description><content:encoded><![CDATA[20年来首个全新机制抗流感新药！罗氏「玛巴洛沙韦片」在华获批上市]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>全球首个CD38单抗新适应症在华获批，2020年销售额41.9亿美元</title><link>https://mp.weixin.qq.com/s/qwuDXmt-lF45-_u0-KFChA</link><description></description><content:encoded><![CDATA[全球首个CD38单抗新适应症在华获批，2020年销售额41.9亿美元]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>医药魔方前沿趋势研究主题分享会 | 苏州站</title><link>https://mp.weixin.qq.com/s/Z3ibAQJ8Zv0C5VSCSSWs-Q</link><description></description><content:encoded><![CDATA[医药魔方前沿趋势研究主题分享会 | 苏州站]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>恒瑞PD-1鼻咽癌适应症获批</title><link>https://mp.weixin.qq.com/s/ZHQFTKQEp8XU6hiPJnKlQA</link><description></description><content:encoded><![CDATA[恒瑞PD-1鼻咽癌适应症获批]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>罗氏PD-L1第3项适应症在华获批！一线治疗NSCLC</title><link>https://mp.weixin.qq.com/s/OmWiGGNQbsthaXhUm7OALQ</link><description></description><content:encoded><![CDATA[罗氏PD-L1第3项适应症在华获批！一线治疗NSCLC]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>【INNOVENT Hiring！】Principal Investigators and Scientists</title><link>https://mp.weixin.qq.com/s/Iu9k2WQr_h6iPJLr1XIYDA</link><description></description><content:encoded><![CDATA[【INNOVENT Hiring！】Principal Investigators and Scientists]]></content:encoded><pubDate>Thu, 29 Apr 2021 16:53:29 +0800</pubDate></item><item><title>PD-1/L1审查：FDA专家组7:2支持保留Tecentriq三阴性乳腺癌适应症</title><link>https://mp.weixin.qq.com/s/FCv8-JgZeVNWh8Fl-m_vSg</link><description></description><content:encoded><![CDATA[PD-1/L1审查：FDA专家组7:2支持保留Tecentriq三阴性乳腺癌适应症]]></content:encoded><pubDate>Wed, 28 Apr 2021 19:09:16 +0800</pubDate></item><item><title>安进2021Q1：生物类似药强劲增长，AMG510审批结果即将见分晓</title><link>https://mp.weixin.qq.com/s/LeU2YIrHpAPeGjzWlzbElA</link><description></description><content:encoded><![CDATA[安进2021Q1：生物类似药强劲增长，AMG510审批结果即将见分晓]]></content:encoded><pubDate>Wed, 28 Apr 2021 19:09:16 +0800</pubDate></item><item><title>直播预告 | 立足2020，展望2021-中国医药行业十大发展趋势</title><link>https://mp.weixin.qq.com/s/hvoWANgIu8PmJztaOgRxbQ</link><description></description><content:encoded><![CDATA[直播预告 | 立足2020，展望2021-中国医药行业十大发展趋势]]></content:encoded><pubDate>Wed, 28 Apr 2021 19:09:16 +0800</pubDate></item><item><title>诺华2021Q1：Entresto 7.89亿美元，年底提交替雷利珠单抗美国上市申请</title><link>https://mp.weixin.qq.com/s/799CUKe8TuCx04VqlwuKCg</link><description></description><content:encoded><![CDATA[诺华2021Q1：Entresto 7.89亿美元，年底提交替雷利珠单抗美国上市申请]]></content:encoded><pubDate>Wed, 28 Apr 2021 19:09:16 +0800</pubDate></item><item><title>赛诺菲2021Q1：度普利尤单抗10.47亿欧元，增长35%</title><link>https://mp.weixin.qq.com/s/bBmRAcbxeK0a8u9N94MXWQ</link><description></description><content:encoded><![CDATA[赛诺菲2021Q1：度普利尤单抗10.47亿欧元，增长35%]]></content:encoded><pubDate>Wed, 28 Apr 2021 19:09:16 +0800</pubDate></item><item><title>两项临床新进展，不一样的CDK4/6抑制剂Trilaciclib</title><link>https://mp.weixin.qq.com/s/vjcr2inEki-djSyKHlnoGQ</link><description></description><content:encoded><![CDATA[两项临床新进展，不一样的CDK4/6抑制剂Trilaciclib]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>直播预告 | 立足2020，展望2021-中国医药行业十大发展趋势</title><link>https://mp.weixin.qq.com/s/WsIXrsDR4lzOJetv0OWYcg</link><description></description><content:encoded><![CDATA[直播预告 | 立足2020，展望2021-中国医药行业十大发展趋势]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>华东医药4.9亿收购道尔生物75%股权，加码抗体药物开发</title><link>https://mp.weixin.qq.com/s/MacXdS-RQUrwnmAu2VdpBA</link><description></description><content:encoded><![CDATA[华东医药4.9亿收购道尔生物75%股权，加码抗体药物开发]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>爱思迈生物申报CD20/CD3双抗，国内第3家</title><link>https://mp.weixin.qq.com/s/dRTv8YmlUj1C_8BA6NJ0cw</link><description></description><content:encoded><![CDATA[爱思迈生物申报CD20/CD3双抗，国内第3家]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>奥赛康申报ALK 5抑制剂，国内第5家</title><link>https://mp.weixin.qq.com/s/jQCVVSRDIKv5xS7H03M-BA</link><description></description><content:encoded><![CDATA[奥赛康申报ALK 5抑制剂，国内第5家]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>原料药断供，一企业拒绝履行集采中选义务</title><link>https://mp.weixin.qq.com/s/K8Qb5w-l0389l_1dBp31nA</link><description></description><content:encoded><![CDATA[原料药断供，一企业拒绝履行集采中选义务]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>黑龙江“8省2区”集采来袭，21个未过评品种带量采购</title><link>https://mp.weixin.qq.com/s/G_AFTVsmYTXVJmfaMozt8Q</link><description></description><content:encoded><![CDATA[黑龙江“8省2区”集采来袭，21个未过评品种带量采购]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item><item><title>今日，强生2款新药申报临床</title><link>https://mp.weixin.qq.com/s/Mdw-STOWbZHe8rkn6ESJAg</link><description></description><content:encoded><![CDATA[今日，强生2款新药申报临床]]></content:encoded><pubDate>Tue, 27 Apr 2021 18:36:27 +0800</pubDate></item></channel></rss>